Targeted alpha therapy with 213Bi.
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.
European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany. alfred.morgenstern@ec.europa.eu
Alfred
A
Morgenstern
Frank
F
Bruchertseifer
Christos
C
Apostolidis
D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D001729:Bismuth; D006801:Humans; D007553:Isotope Labeling; D009369:Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D011868:Radioisotopes; D019275:Radiopharmaceuticals; D001729:Bismuth